This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Adam, H. J.
Right arrow Articles by Zhanel, G. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adam, H. J.
Right arrow Articles by Zhanel, G. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2009, p. 4915-4920, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00078-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates{triangledown}

Heather J. Adam,1* Nancy M. Laing,2 C. Richard King,3 Ben Lulashnyk,2 Daryl J. Hoban,1,2 and George G. Zhanel2

Diagnostic Services of Manitoba/Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada,1 Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada,2 TaiGen Biotechnology Co. Ltd., Taipei, Taiwan3

Received 20 January 2009/ Returned for modification 17 April 2009/ Accepted 1 September 2009

The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC90/range [µg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/≤0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC90/range [µg/ml]; Escherichia coli, 32/≤0.015 to ≥512; Klebsiella pneumoniae, 2/≤0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to ≥512; Pseudomonas aeruginosa, 32/≤0.015 to ≥512; Acinetobacter baumannii, 1/0.12 to 16).

* Corresponding author. Mailing address: Department of Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. Phone: (204) 787-8678. Fax: (204) 787-4699. E-mail: hadam{at}hsc.mb.ca

{triangledown} Published ahead of print on 8 September 2009.

Antimicrobial Agents and Chemotherapy, November 2009, p. 4915-4920, Vol. 53, No. 11
0066-4804/09/$08.00+0     doi:10.1128/AAC.00078-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»